Want to see SYRA full AI Analyst Report?
Top Page
Syra Health Corp. Class A
(OTC:SYRA)
Select Model
Select Model
Rating:57Neutral
Price Target:
$0.86
▼(-5.60% Downside)
Action:Reiterated
Date:09/22/26
The score is primarily driven by improving financial performance (revenue rebound and a return to profitability) and supportive technical trends. These positives are tempered by a very high P/E valuation and lingering durability risks due to thin margins and still-developing cash flow consistency, with corporate actions adding potential dilution considerations.
Positive Factors
Revenue and profit turnaround
The sharp TTM revenue rebound and return to profitability indicate improved commercial traction and operating execution after prior losses. If growth converts into repeatable contracted revenue, it can broaden the company’s client base and create a foundation for more durable earnings over the next several quarters.
Negative Factors
Very thin profitability
Margins remain narrow, leaving limited protection if labor, delivery, or administrative costs rise or revenue growth slows. Such low profitability makes earnings sensitive to modest execution changes and means Syra must sustain strong growth and cost control before its improved results can be viewed as consistently durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and profit turnaround
The sharp TTM revenue rebound and return to profitability indicate improved commercial traction and operating execution after prior losses. If growth converts into repeatable contracted revenue, it can broaden the company’s client base and create a foundation for more durable earnings over the next several quarters.
Read all positive factors
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.79M
Dividend YieldN/A
Average Volume (3M)32.57K
Price to Earnings (P/E)92.2
Beta (1Y)1.44
Revenue Growth0.32%
EPS GrowthN/A
CountryUS
Employees89
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding13,850,279
10 Day Avg. Volume19,283
30 Day Avg. Volume32,574
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.49
Price to Sales (P/S)0.14
P/FCF Ratio-2.28
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda45.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syra Health Corp. Class A Business Overview & Revenue Model
Company Description
Syra Health Corp. is a U.S.-based healthcare services company offering a diverse portfolio of solutions. Their core offerings span health education, population health management, behavioral and mental health support, healthcare workforce solutions...
How the Company Makes Money
Syra Health generates revenue primarily by providing healthcare-related services to organizations (such as healthcare providers, employers, and public-sector entities) under contracted engagements. Key revenue streams include (1) service fees from...
Syra Health Corp. Class A Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.Positive Updates
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Negative Updates
Delisting from NASDAQ
The company announced a strategic decision to voluntarily delist from the NASDAQ capital market to reduce costs and strengthen core fundamentals.
Read all updates
Q1-2025 Updates
Positive
Negative
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Read all positive updates
Company Guidance
During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.Syra Health Corp. Class A Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.09M | 7.23M | 7.98M | 5.52M | 5.62M | 1.41M |
| Gross Profit | 3.18M | 2.49M | 1.65M | 1.41M | 1.06M | 430.35K |
| EBITDA | 146.26K | -862.60K | -3.68M | -2.84M | -2.07M | -3.07K |
| Net Income | 130.75K | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K |
Balance Sheet | ||||||
| Total Assets | 3.83M | 2.77M | 3.68M | 4.92M | 2.32M | 536.89K |
| Cash, Cash Equivalents and Short-Term Investments | 2.12M | 1.61M | 2.40M | 3.28M | 3.34K | 100.01K |
| Total Debt | 149.34K | 143.79K | 452.08K | 248.10K | 934.84K | 342.86K |
| Total Liabilities | 1.20M | 674.74K | 800.76K | 910.07K | 1.61M | 544.04K |
| Stockholders Equity | 2.63M | 2.10M | 2.88M | 4.01M | 710.10K | -7.15K |
Cash Flow | ||||||
| Free Cash Flow | 109.58K | -447.85K | -2.94M | -2.77M | -2.37M | -94.49K |
| Operating Cash Flow | 109.68K | -447.75K | -2.93M | -2.76M | -2.24M | -88.20K |
| Investing Cash Flow | -107.00 | -107.00 | -11.11K | -15.25K | -121.26K | -6.29K |
| Financing Cash Flow | -291.75K | -332.82K | 2.06M | 6.05M | 2.27M | 191.50K |
Syra Health Corp. Class A Technical Analysis
Neutral
0.91
Price Trends
0.84
Negative
0.71
Positive
0.45
Positive
Market Momentum
>-0.01
Positive
45.94
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Neutral. The current price of 0.91 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.84, and above the 200-day MA of 0.45, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.94 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 49 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syra Health Corp. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $4.62B | 23.48 | 47.30% | 0.69% | 14.02% | 31.92% | |
65 Neutral | $1.25B | 491.94 | -1.27% | 2.19% | 11.32% | -92.59% | |
57 Neutral | $11.79M | 92.22 | 5.62% | ― | 0.32% | ― | |
52 Neutral | $1.75B | -19.43 | -5.21% | ― | 3.99% | 51.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $36.11M | -0.18 | -115.58% | ― | -32.40% | -969.05% | |
44 Neutral | $137.70M | -10.24 | -12.52% | 4.45% | -8.71% | 26.89% |
* Healthcare Sector Average
SYRA
Syra Health Corp. Class A
0.86
0.76
768.69%
USPH
US Physical Therapy
82.96
-5.15
-5.84%
SGRY
Surgery Partners
13.71
-6.88
-33.40%
DCGO
DocGo
0.35
-0.92
-72.62%
AIRS
Airsculpt Technologies
1.82
-6.73
-78.71%
CON
Concentra Group Holdings Parent, Inc.
36.40
15.76
76.35%
Syra Health Corp. Class A Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Syra Health Stockholders Approve Board and Equity Plan
Positive
Jul 23, 2026
On July 23, 2026, Syra Health Corp. held its Annual Meeting of Stockholders, with 13,664,105 shares represented, including high-vote Class B shares that helped constitute a quorum. Stockholders elected five directors, including Priya Prasad and Dr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.